Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025
Clinical effect of Shugan Jieyu San for improving liver function and alleviating depression in patients with triple negative breast cancer.
Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Current and future therapies for triple-negative breast cancer.Journal of hematology & oncology · 2026Review
- Xiaoyao San alleviates emotional distress - induced TNBC growth through augmenting intratumoral CD8Frontiers in immunology · 2026Article
- Review
- Progress on the mechanism of natural polysaccharides in the treatment of arthritis.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic effect of a self-formulated Traditional Chinese Medicine (TCM), Shugan Jieyu San, on improvement of liver function and depression alleviation in the patients with triple negative breast cancer (TNBC).
methodsA total of 60 patients diagnosed with TNBC and depression were enrolled and randomly assigned to either the control group (receiving routine tumor treatment and duloxetine) or the treatment group (receiving the TCM in addition to routine treatment).
resultsBoth treatment and control groups showed a reduction in depressive symptoms and improved daily living abilities after treatment. However, the treatment group demonstrated significantly better outcomes compared to the control group. Furthermore, the levels of dopamine and serotonin in the serum increased in both groups after 8 weeks of treatment, while the treatment group exhibited superior results.
conclusionsThis TCM showed promising results in reducing depressive symptoms and improving daily abilities in patients with TNBC and comorbid depression, which was verified by the increase in serum levels of dopamine and serotonin, suggesting the potential involvement of these neurotransmitters in the therapeutic effects of this TCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.